Although a limitation of the study is that only acute and subacute time points were included, our goal was specifically to evaluate hAECs in the context of tPA therapy, which itself is only clinically relevant for this post-stroke period given its narrow therapeutic time window and short half-life. The gene discussed is PLAT; the disease is Stroke.